title: Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
abstract: OBJECTIVE
  The use of once-weekly exenatide in type 2 diabetes mellitus is well supported, but little is known about its effectiveness in type 1 diabetes. The objective of this study was to determine the clinical efficacy of once-weekly exenatide on glycemic control in patients with type 1 diabetes when added to basal-bolus insulin therapy.
  
  
  METHODS
  For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included. Demographic information, glycated hemoglobin (A1C), body weight, body mass index, systolic and diastolic blood pressures, total daily insulin dose, basal and bolus insulin doses, 28-day continuous subcutaneous insulin infusion glucose average and incidence of hypoglycemia were collected at baseline and 3 months after beginning therapy with once-weekly exenatide.
  
  
  RESULTS
  An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria. Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).
  
  
  CONCLUSIONS
  This study revealed that the addition of once-weekly exenatide to insulin therapy for type 1 diabetes patients leads to significant improvements in A1C, body weight, body mass index and insulin doses.
authors.affiliation: AstraZeneca LP, Fort Washington, Pennsylvania, USA.
authors.forename: Andrea N
authors.initials: AN
authors.lastname: Traina
authors.affiliation: AstraZeneca LP, Fort Washington, Pennsylvania, USA; St. John Fisher College, Wegmans School of Pharmacy, Rochester, USA. Electronic address: mlull@sjfc.edu.
authors.forename: Melinda E
authors.initials: ME
authors.lastname: Lull
authors.affiliation: MedStar Union Memorial Hospital, Baltimore, USA.
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Hui
authors.affiliation: Boston Medical Center, Boston, USA.
authors.forename: Toni M
authors.initials: TM
authors.lastname: Zahorian
authors.affiliation: Rochester General Health System, Rochester, USA.
authors.forename: Jane
authors.initials: J
authors.lastname: Lyons-Patterson
mesh_terms: D000328:Adult; D015992:Body Mass Index; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D010455:Peptides / Q000627:therapeutic use*; D012189:Retrospective Studies; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D014688:Venoms; D000077270:Exenatide
keywords: GLP-1 (glucagon-like peptide-1); diabetes; diabète; exenatide; exénatide; glucagon-like peptide-1; incretin; incrétine